NCI-2018-01788, NCT03670966: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome |
|
|
| Suspended | 1/2 | 30 | US | Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Cyclophosphamide, (-)-Cyclophosphamide, Asta B 518, B-518, WR-138719, Total-Body Irradiation, Total Body Irradiation, SCT_TBI, Whole Body Irradiation, Whole-Body Irradiation, TBI, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Bone Marrow Transplantation, Bone Marrow Grafting, BMT, Mycophenolate Mofetil, 115007-34-6, MMF, Cellcept, Recombinant Granulocyte Colony-Stimulating Factor, 143011-72-7, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, Fludara, Fludarabine-5''-Monophosphate, SH T 586, Tacrolimus, Prograf, Protopic, FK 506, FK-506, Tacforius, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Biological Sample Collection | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm | 06/25 | 03/27 | | |
